Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis

被引:69
作者
Mayer-Hamblett, Nicole [1 ,2 ]
Kronmal, Richard A. [3 ]
Gibson, Ronald L. [1 ,2 ]
Rosenfeld, Margaret [1 ,2 ]
Retsch-Bogart, George [4 ]
Treggiari, Miriam M. [5 ]
Burns, Jane L. [1 ,2 ]
Khan, Umer [2 ]
Ramsey, Bonnie W. [1 ,2 ]
机构
[1] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[2] Seattle Childrens Hosp, Seattle, WA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Univ N Carolina, Dept Pediat, Chapel Hill, NC USA
[5] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA
关键词
new acquisition; early intervention; eradication; clinical outcome; YOUNG-CHILDREN; COLONIZATION; PREDICTORS; MORTALITY; TOBRAMYCIN; INFECTION; GENOTYPE;
D O I
10.1002/ppul.21525
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Rationale The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown. Objectives: To determine if failure of antibiotic therapy to eradicate Pa and frequency of Pa recurrence are associated with increased exacerbation risk. Methods: The cohort included 282 children with CF who participated in the EPIC trial ages 1-12 with newly acquired Pa, defined as either a first lifetime Pa positive respiratory culture or positive after two years of negative cultures (past isolation of Pa but > 2 years prior to the trial). All received antibiotics to promote initial eradication followed by 15 months of intermittent maintenance antibiotics. Quarterly cultures were used to define initial eradication success and subsequent number of Pa recurrences. A standardized symptombased definition of exacerbation was utilized. Cox proportional hazards models were used to estimate exacerbation risk. Results: Failure to initially eradicate Pa was associated with exacerbation risk (hazard ratio [HR]: 2.49, 95% confidence interval [CI] 1.26, 4.93). In 245/282 with successful initial eradication during the trial, past isolation of Pa > 2 years before the trial was the most significant predictor of exacerbation (HR 1.62, 95% CI 1.12, 2.35). In 37/282 who failed initial eradication, persistent Pa during the maintenance phase (1 or more Pa recurrences after failure to initially eradicate) added even greater exacerbation risk (HR 4.13, 95% CI 1.28, 13.32). Conclusions: Children with CF who fail to eradicate after initial antibiotic treatment are at higher risk of subsequent exacerbation, suggesting clinical benefit to successful early eradication of Pa infection. Pediatr Pulmonol. 2012; 47: 125-134. (C) 2011 Wiley Periodicals, Inc.
引用
收藏
页码:125 / 134
页数:10
相关论文
共 50 条
  • [31] Pseudomonas aeruginosa biofilms in cystic fibrosis
    Hoiby, Niels
    Ciofu, Oana
    Bjarnsholt, Thomas
    [J]. FUTURE MICROBIOLOGY, 2010, 5 (11) : 1663 - 1674
  • [32] Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial
    Ratjen, Felix
    Munck, Anne
    Kho, Pearl
    Angyalosi, Gerhild
    [J]. THORAX, 2010, 65 (04) : 286 - 291
  • [33] The Effect of Early Pseudomonas aeruginosa Treatment on Lung Function in Pediatric Cystic Fibrosis
    Amin, Reshma
    Lam, Michelle
    Dupuis, Annie
    Ratjen, Felix
    [J]. PEDIATRIC PULMONOLOGY, 2011, 46 (06) : 554 - 558
  • [34] Efficacy and Future of the Aerosoltherapy in the Treatment of Cystic Fibrosis Patients Infected by Pseudomonas aeruginosa
    Rognon, Amelie
    Curti, Christophe
    Montana, Marc
    Terme, Thierry
    Rathelot, Pascal
    Vanelle, Patrice
    [J]. THERAPIE, 2011, 66 (06): : 481 - 491
  • [35] The Approach to Pseudomonas aeruginosa in Cystic Fibrosis
    Talwalkar, Jaideep S.
    Murray, Thomas S.
    [J]. CLINICS IN CHEST MEDICINE, 2016, 37 (01) : 69 - +
  • [36] Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis
    Moore, J. E.
    Mastoridis, P.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) : 259 - 267
  • [37] Cyanide in bronchoalveolar lavage is not diagnostic for Pseudomonas aeruginosa in children with cystic fibrosis
    Stutz, M. D.
    Gangell, C. L.
    Berry, L. J.
    Garratt, L. W.
    Sheil, B.
    Sly, P. D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (03) : 553 - 558
  • [38] The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis
    Emiralioglu, N.
    Yalcin, E.
    Meral, A.
    Sener, B.
    Dogru, D.
    Ozcelik, U.
    Kiper, N.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) : 419 - 423
  • [39] Impact of eradication of Pseudomonas aeruginosa on survival in Mexican patients with cystic fibrosis
    Bustamante, Adriana Ester
    Mercado-Longoria, Roberto
    Tijerina-Menchaca, Rolando
    Mas-Trevino, Marcela
    Torres-Rodriguez, Julian
    [J]. REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2014, 66 (04): : 307 - 313
  • [40] Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis
    Blanchard, Ana C.
    Horton, Eric
    Stanojevic, Sanja
    Taylor, Louise
    Waters, Valerie
    Ratjen, Felix
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (03) : 395 - 400